Jung then obtained a NATO Postdoctoral Fellowship to work with Albert Eschenmoser at the Eidgenössische Technische Hochschule in Zürich, Switzerland.

[2] Jung's research is focused on the development of new reactions for organic synthesis, including the Jung "non-aldol aldol" protocol, an alternate method for obtaining aldol products without using the classical aldol reaction.

[3] He has also developed chemical syntheses for a variety of natural products with antitumor and antiviral properties including tedanolides,[4][5][6] oxetanocin,[7] halomons,[8] and xestobergsterol.

[9] Other research interests include the bridged Robinson annulation and the mixed Lewis acid Diels-Alder process.

[10] Jung's research group developed an antagonist of the androgen receptor enzalutamide, which is a pharmaceutical drug used for the treatment of hormone refractory prostate cancer.